RelabotulinumtoxinA improves frown lines, crow’s feet simultaneously for up to 6 months
Key takeaways:
- When treated separately, 71% of patients treated for frown lines and 45% treated for crow’s feet saw improvements.
- When treated together, these percentages increased (72% and 55%, respectively).
New phase 3 data showed that a single dose of relabotulinumtoxinA significantly improved glabellar and lateral canthal lines when treated alone or simultaneously with a duration of up to 6 months, Galderma announced in a press release.
These results are from the randomized, double-blind, placebo-controlled, phase 3 READY-3 trial, which assessed the safety and efficacy of relabotulinumtoxinA in patients with moderate to severe glabellar and lateral canthal lines, also known as frown lines and crow’s feet, respectively.
“These positive data from the phase 3 READY-3 trial show that relabotulinumtoxinA significantly improves both frown lines and crow’s feet when treated at the same time, with results maintained for 6 months,” Bill Andriopoulos, PhD, vice president of U.S. medical affairs at Galderma, told Healio. “Taken together with results from the phase 3 READY-1 and READY-2 trials as well as the phase 3b studies, these data reinforce relabotulinumtoxinA’s ability to be a fast-acting and long-lasting solution, improving frown lines and crow’s feet as early as day 1.”
During the trial, relabotulinumtoxinA was administered as a single-area treatment or a simultaneous treatment on both areas and then compared with placebo.
Results showed the study met its co-primary endpoints of at least a two-grade improvement in line severity 1 month after beginning treatment. Among those that received a single-area treatment, 71% and 45% treated for frown lines and crow’s feet, respectively, achieved the end point (P = .001).
Similarly, 72% of those that received simultaneous treatment saw improvement in their frown lines, whereas 55% saw improvement in their crow’s feet (P = .001).
According to investigator-reported response rates after 1 month of treatment, 94% to 96% of patients had none or mild frown lines vs. 2% of placebo, whereas 79% to 84% of patients had none or mild crow’s feet vs. 20% of placebo (P = .001 for both).
Baseline line severity returned after a median time of 6 months, according to investigator- and patient-reported scores, with simultaneously-treated patients achieving slightly longer results than single-area-treated patients (24-25 weeks vs. 25-27 weeks).
Patients treated with relabotulinumtoxinA experienced low rates of adverse events compared with placebo (4%-9% vs. 5%). No serious adverse events were reported.
Editor's note: On Jan. 22, the quote attribution was changed to Bill Andriopoulos. The editors regret the error.